2002
DOI: 10.1590/s0037-86822002000400001
|View full text |Cite
|
Sign up to set email alerts
|

A quimioprofilaxia de doenças transmissíveis por transfusão em componentes lábeis hemoterápicos

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2003
2003
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 11 publications
0
3
0
Order By: Relevance
“…Two studies have shown that it has disadvantages: alkylation of proteins and formation of neoantigens after repeated treatments (16,18) . In order to increase the safety of the hemotherapy component that has been treated, this product is removed through fixation to an external matrix (which remains inside the collection bag) throughout the storage period (1) .…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Two studies have shown that it has disadvantages: alkylation of proteins and formation of neoantigens after repeated treatments (16,18) . In order to increase the safety of the hemotherapy component that has been treated, this product is removed through fixation to an external matrix (which remains inside the collection bag) throughout the storage period (1) .…”
Section: Discussionmentioning
confidence: 99%
“…The current processes for pathogen inactivation in blood therapy components (red cell concentrate, platelets, plasma or cryoprecipitate) involve contact by the inactivation agent and subsequent removal processes by systems integrated with the collection and processing procedure (1) . These processes may cause damage to the blood components, thereby resulting in shortening the in vivo lifespan of red cells or platelets, or diminished levels of coagulation proteins in fresh frozen plasma (2) .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation